Chemotherapy-induced nausea and vomiting

Cancer Journal

Volumn 14, Issue 2, 2008, Pages 85-93

  Lohr, Lisa ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Antiemetic; Casopitant; Chemotherapy; Chemotherapy induced nausea and vomiting (CINV); Corticosteroid; Gabapentin; Neurokinin receptor antagonist; Olanzapine; Serotonin antagonist

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALEMTUZUMAB; ALTRETAMINE; AMIFOSTINE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; ARSENIC TRIOXIDE; ASPARAGINASE; ASPARAGINASE MACROGOL; AZACITIDINE; BEVACIZUMAB; BEXAROTENE; BLEOMYCIN; BLEOMYCIN SULFATE; BORTEZOMIB; BUSULFAN; CAPECITABINE; CARBOPLATIN; CARMUSTINE; CASOPITANT; CETUXIMAB; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CLADRIBINE; COLLAR; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DASATINIB; DAUNORUBICIN; DENILEUKIN DIFTITOX; DEXAMETHASONE; DOCETAXEL; DOLASETRON MESILATE; DOXORUBICIN; DRONABINOL; DROPERIDOL; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; FLUDARABINE PHOSPHATE; FLUOROURACIL; GABAPENTIN; GEFITINIB; GEMCITABINE; GEMTUZUMAB OZOGAMICIN; GRANISETRON; HALOPERIDOL; HYDROXYUREA; IDARUBICIN; IFOSFAMIDE; IMATINIB; IRINOTECAN; LAPATINIB; LENALIDOMIDE; LOMUSTINE; LORAZEPAM; MELPHALAN; MERCAPTOPURINE; MESNA; METHOTREXATE; METHYLPREDNISOLONE SODIUM SUCCINATE; METOCLOPRAMIDE; MITOMYCIN C; MITOXANTRONE; NABILONE; NAVELBINE; NELARABINE; OLANZAPINE; ONDANSETRON; OXALIPLATIN; PACLITAXEL; PALONOSETRON; PANITUMUMAB; PEMETREXED; PENTOSTATIN; PLACEBO; PROCARBAZINE; PROCHLORPERAZINE MALEATE; PROMETHAZINE; RAZOXANE; RECOMBINANT INTERLEUKIN 2; RETINOIC ACID; RITUXIMAB; SORAFENIB; STREPTOZOCIN; SUNITINIB; TABLOID; TEMOZOLOMIDE; TEMSIROLIMUS; TENIPOSIDE; THALIDOMIDE; THIOTEPA; TOPOTECAN; TRASTUZUMAB; TRIMETREXATE GLUCURONATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE SULFATE; VINCRISTINE; VINCRISTINE SULFATE; VORINOSTAT; BENZODIAZEPINE DERIVATIVE; CANNABINOID; CORTICOSTEROID; DOPAMINE RECEPTOR BLOCKING AGENT; NEUROKININ 1 RECEPTOR; SEROTONIN ANTAGONIST;

ADD ON THERAPY; AMNESIA; ANTICHOLINERGIC EFFECT; ATAXIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DEPRESSION; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL TRIAL; CONFUSION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG ACTIVITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; EVENING DOSAGE; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT; HEADACHE; HICCUP; HUMAN; HYPERGLYCEMIA; INCREASED APPETITE; INSOMNIA; JAUNDICE; LOW DRUG DOSE; MANIA; MOOD DISORDER; MORNING DOSAGE; NERVOUSNESS; NEUROPATHIC PAIN; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; RESPIRATION DEPRESSION; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TESTIS CANCER; TREATMENT DURATION; TREMOR; VERTIGO; WEIGHT GAIN; XEROSTOMIA; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; NAUSEA; NEOPLASM; VOMITING;

ADRENAL CORTEX HORMONES; ANTIEMETICS; ANTINEOPLASTIC AGENTS; BENZODIAZEPINES; CANNABINOIDS; DOPAMINE ANTAGONISTS; HUMANS; NAUSEA; NEOPLASMS; RECEPTORS, NEUROKININ-1; SEROTONIN ANTAGONISTS; VOMITING;

EID: 47249165621     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e31816a0f07     Document Type: Review

References (48)

1. Ettinger DS, Bierman PJ, Bradbury B, et al. Antiemesis: clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007;5:12-33.
2. Petrella T, Joy A, Young S, et al. Identifying patients at high risk for moderate to severe nausea and vomiting following chemotherapy: the development and validation of a prediction tool for the practicing oncologist [Abstract]. Support Care Cancer. 2006;14:598.
3. Grunberg SM, Osoba D, Hesketh PJ, et al. Evaluation of new antiemetic agents and definition of antineoplastic agents emetogenicity - an update. Support Care Cancer. 2005;13:80-84.
4. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006;24:2932-2947.
5. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997;15: 103-109.
6. The Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol. 2006;17:20-28.
7. Hamadani M, et al. Relative efficacy of various 5-hydroxytyptamine receptor antagonists in the prevention and control of acute nausea and vomiting associated with platinum-based chemotherapy. J Clin Oncol. 2006;24:8623. Abstract.
8. Jordan K, Schmoll HJ, Aapro MS, et al. Comparative activity of antiemetic drugs. Crit Rev Oncol Hematol. 2007;61:162-175.
9. Jordan K, Hinke A, Grothey A, et al. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer. 2007;15:1023-1033.
10. Lindley C, Goodin S, McCune, et al. Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy. Am J Clin Oncol. 2005;28:270-276.
11. Hickok JT, Roscoe JA, Morrow GR, et al. 5-Hydroxytryptamine receptor antagonists versus prochlorperazine for control for delayed nausea caused by doxorubicin: a URCC CCOP randomized controlled trial. Lancet Oncol. 2005;6:765-772.
12. Geling O, Eichler HG. Should 5-hydroxytryptamine-3 antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systemic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol. 2005;23:1289-1294.
13. Lachaine J, Laurier C. Cost-efficacy analysis of ondansetron regimens for control of emesis induced by non-cisplatin, moderately emetogenic chemotherapy. Am J Health Syst Pharm. 2002;59:1837-1846.
14. Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondan-setron. Ann Oncol. 2003;14:1570-1577.
15. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5HT3 antagonist. Cancer. 2003;98:2473-2482.
16. Aapro MS, Grunberg SM, Manikhas GM, et al. A phase II, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol. 2006;17:1441-1449.
17. Grote T, Hajdenberg J, Cartmell A, et al. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J Support Oncol. 2006;4:403-408.
18. Einhorn LH, Brames MJ, Dreicer R, et al. Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patient receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer. 2007;15:1293-1300.
19. Shi Y, He S, Yang S, et al. Ramosetron versus ondansetron in the prevention of chemotherapy-induced gastrointestinal side effects: a prospective randomized controlled study. Chemotherapy. 2007;53:44-50.
20. Navari RM, Province PS. Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006;11:137-151.
21. Grunberg SM. Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. Ann Oncol. 2007;18:233-240.
22. Ioannidis JP, Hesketh PJ, Lau J. Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J Clin Oncol. 2000;18:3409-3422.
23. The Italian Group for Antiemetic Research. Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide. J Clin Oncol. 2004;22:725-729.
24. The Italian Group for Antiemetic Research. Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. J Clin Oncol. 1998;16:2937-2942.
25. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant 052 Study Group. J Clin Oncol. 2003;21:4112-4119.
26. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin-1 antagonist aprepitant to standard antiemetic therapy improves control on chemotherapy-induced nausea and vomiting: Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97:3090-3098.
27. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005;23:2822-2830.
28. Schmoll HJ, AApro MS, Poli-Bigelli S, et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol. 2006;17:1000-1006.
29. Massaro AM, Lenz KL. Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting. Ann Pharmacother. 2005;39:77-85.
30. Shadle CR, Lee Y, Majumdar AK, et al. Evaluation of potential inductive effects of aprepitant on cytochrome P4503A4 and 2C9 activity. J Clin Pharmacol. 2004;44:215-223.
31. McCrea JB, Majumdar AK, Goldberg MR, et al. Effects of the neurokinin-1 receptor antagonist aprepitant of the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther. 2003;74:17-24.
32. Dando TM, Perry CM. Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs. 2004;64:777-794.
33. Depré M, Van Hecken A, Oeyen M, et al. Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur J Pharmacol. 2005;61:341-346.
34. Hesketh PJ, Grunberg SM, Herrstedt J, et al. Combined data from two phase III trials of NK-1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer. 2006;14:354-360.
35. Slatkin NE. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis. J Support Oncol. 2007;5(S3):1.
36. Meiri E, et al. Dronabinol treatment of delayed chemotherapy-induced nausea and vomiting. J Clin Oncol. 2005;23:8018.
37. Meiri E, Jhangiani H, Vredenburgh JJ, et al. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin. 2007;23:533-543.
38. Davis MP. Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain. Expert Opin Investig Drugs. 2008;17:85-95.
39. Srivastava M, Brito-Dellan N, Davis MP, et al. Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J Pain Symptom Manage. 2003;25:578-582.
40. Jackson WC, Tavernier L. Olanzapine for intractable nausea in palliative care patients. J Palliative Med. 2003;6:251-255.
41. Passik SD, Navari RM, Jung SH, et al. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. Cancer Invest. 2004;22:383-388.
42. Passik SD, Kirsh KL, Theobald DE, et al. A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. J Pain Symptom Manage. 2003;25:485-488.
43. Navari RM, Einhorn LH, Passik SD, et al. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer. 2005;13:529-534.
44. Navari RM, Einhorn LH, Loehrer PJ Sr, et al. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer. 2007;15:1285-1292.
45. Guttuso T Jr, Roscoe J, Griggs J. Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer. Lancet. 2003;361:1703-1705.
46. Menendez-Leal C, Quijano C, Menendez-Rivera G, et al. Prophylaxis of delayed chemotherapy induced nausea and vomiting with gabapentin. Support Care Cancer. 2006;14:600.
47. Rolski J, Ramlau R, Dediu M, et al. Randomized phase II trial of the neurokinin-1 receptor antagonist casopitant mesylate with ondansetron/ dexamethasone for chemotherapy-induced nausea/vomiting in patients receiving highly emetogenic chemotherapy. J Clin Oncol. 2006;24 (18 suppl):8513.
48. Arpornwirat W, Albert I, Hansen VL, et al. Multi-center, randomized, double-blind, ondansetron-controlled, dose-ranging, parallel group trial of the neurokinin-1 receptor antagonist casopitant mesylate for chemotherapy-induced nausea/vomiting in patients receiving moderately emetogenic chemotherapy. J Clin Oncol. 2006;24 (18 suppl):8512.